Sprint Bioscience AB (publ) and Bayer HealthCare have entered into a collaboration and license agreement for the research, development, and commercialization of oncology drug candidates. The license, which is on an exclusive basis, is the first Sprint Bioscience’s has made with a global pharmaceutical company concerning its methodology in tumor metabolism for developing drug candidates with the aim to develop new and effective oncology drugs.
Under the agreement, Bayer will pay an amount upon the signing of the agreement. In addition, Sprint Bioscience will receive milestone payments at different development stages as well as royalties on sales of future products. As part of the agreement the parties will also carry out research collaboration with the aim to further develop Sprint Bioscience’s existing oncology substances. These substances are also covered by Sprint Bioscience’s entitlement to milestone payments and royalties on sales.
Lindahl assisted Sprint Bioscience through Anders Burén and Jonas Westerberg (Life Sciences) and Erik Brändt (Competition).